The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have jointly released a notification regarding the adjustment of the narcotics and psychotropic substances catalog in China. The updated catalog, which will come into effect on October 1, 2023, sees the addition of three new varieties, further refining the classification of controlled substances.
New Additions and Classification Changes
The newly added substances include etomidate and EVT201, both of which are classified as Category II psychotropics, as well as a narcotic drug. Modafinil, previously a higher classification, has been downgraded to a Category II psychotropic drug. These changes reflect China’s ongoing efforts to adapt its narcotics control policies to meet current medical and public health needs.
Historical Context and Updates
China first released its narcotics and psychotropics list in November 2013, which initially included 121 anesthetic drugs, 68 Category I psychotropic drugs, and 81 Category II psychotropic drugs. Since then, the list has been updated twice, and now contains 124 anesthetic drugs, 69 Category I psychotropic drugs, and 88 Category II psychotropic drugs. The latest adjustments aim to ensure that the catalog remains comprehensive and effective in regulating the use and distribution of controlled substances.-Fineline Info & Tech
